Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ROSY-S: Rollover Study for Participants Who Have Completed a Previous Study With Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Benefit From Continued Treatment

NCT07691970 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07691970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07691970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ROSY-S: Rollover Study for Participants Who Have Completed a Previous Study With Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Benefit From Continued Treatment
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
August 31, 2026
Completion date
December 30, 2032
Enrollment
1,072 (estimated)
Sites
128

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis cutaneous lupus e myopathies systemic lupus erythematosus